The offeror’s proposed work plan aims to identify, characterize and optimize non-toxic, low molecular weight agents as adjuvants that a) enhance protein antigen accumulation and release in non-immune and immune cells after intramuscular administration of mRNA vaccine and b) stimulate innate immune pathway-activation in antigen presenting cells.